MG
ACAD icon

Michael Gelband’s Acadia Pharmaceuticals ACAD Stock Holding History

Michael Gelband’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-76,183
Closed -$2.03M – 1501
2025
Q4 		$2.03M Buy
+76,183
New +$1.82M 0.02% 760
2025
Q2 		– Sell
-37,491
Closed -$623K – 1415
2025
Q1 		$623K Sell
37,491
-33,295
-47% -$605K 0.01% 1061
2024
Q4 		$1.3M Buy
70,786
+11,885
+20% +$192K 0.01% 858
2024
Q3 		$906K Buy
58,901
+10,816
+22% +$180K 0.01% 999
2024
Q2 		$781K Sell
48,085
-71,407
-60% -$1.15M 0.01% 1101
2024
Q1 		$2.21M Buy
+119,492
New +$2.96M 0.02% 663
2023
Q4 		– Sell
-276,829
Closed -$5.77M – 1401
2023
Q3 		$5.77M Buy
+276,829
New +$7.52M 0.06% 342
2023
Q2 		– Sell
-98,890
Closed -$1.86M – 1798
2023
Q1 		$1.86M Sell
98,890
-367,953
-79% -$7.01M 0.02% 911
2022
Q4 		$7.43M Buy
466,843
+405,846
+665% +$6.34M 0.11% 242
2022
Q3 		$998K Buy
60,997
+16,224
+36% +$263K 0.01% 1103
2022
Q2 		$631K Sell
44,773
-28,988
-39% -$541K 0.01% 1271
2022
Q1 		$1.79M Buy
+73,761
New +$1.78M 0.02% 838
2021
Q3 		– Sell
-30,188
Closed -$736K – 2032
2021
Q2 		$736K Buy
30,188
+4,229
+16% +$95.5K 0.01% 1161
2021
Q1 		$670K Sell
25,959
-29,597
-53% -$1.3M 0.01% 1162
2020
Q4 		$2.97M Buy
55,556
+40,844
+278% +$2.03M 0.03% 400
2020
Q3 		$607K Sell
14,712
-126,294
-90% -$5.45M 0.01% 914
2020
Q2 		$6.83M Buy
141,006
+132,778
+1,614% +$6.37M 0.18% 107
2020
Q1 		$348K Sell
8,228
-38,553
-82% -$1.59M 0.02% 606
2019
Q4 		$2M Buy
+46,781
New +$2.04M 0.04% 344

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Michael Gelband's ACAD Position: Q1 2026 in Review

Michael Gelband sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 76,183 shares — an estimated $2.03M sold.

Michael Gelband first reported a position in ACAD in Q4 2019 and held it in 19 quarters. The position peaked at $7.43M in Q4 2022. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Michael Gelband reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 76,183 Acadia Pharmaceuticals shares in Q1 2026, an estimated $2.03M.
  • Michael Gelband first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 19 quarters.
  • Michael Gelband's Acadia Pharmaceuticals position peaked at $7.43M in Q4 2022.
  • 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.